Nabriva Therapeutics AG (NASDAQ:NBRV)‘s stock had its “buy” rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued on Friday. They currently have a $16.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 74.86% from the company’s current price.

The analysts wrote, “Yesterday, after market close, Nabriva announced that Elyse Seltzer, M.D., is resigning as CMO effective 9/30/2017.””

Several other research firms have also recently commented on NBRV. Wedbush reiterated an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Thursday, August 10th. HC Wainwright restated a “buy” rating and issued a $18.00 target price (up previously from $16.00) on shares of Nabriva Therapeutics AG in a report on Monday. ValuEngine cut shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, SunTrust Banks, Inc. started coverage on shares of Nabriva Therapeutics AG in a report on Friday, August 25th. They issued a “buy” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Nabriva Therapeutics AG currently has an average rating of “Buy” and an average price target of $16.25.

Shares of Nabriva Therapeutics AG (NASDAQ NBRV) opened at 9.15 on Friday. The company’s 50-day moving average is $9.73 and its 200-day moving average is $10.39. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $12.75. The stock’s market cap is $245.57 million.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million. Equities analysts anticipate that Nabriva Therapeutics AG will post ($2.34) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/01/nabriva-therapeutics-ag-nbrv-rating-reiterated-by-cantor-fitzgerald.html.

In related news, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $10.94, for a total value of $143,609.38. Following the completion of the sale, the insider now owns 2,583,229 shares in the company, valued at approximately $28,260,525.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 241,923 shares of company stock valued at $2,567,274. 2.75% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in NBRV. Renaissance Technologies LLC purchased a new position in shares of Nabriva Therapeutics AG during the fourth quarter worth approximately $103,000. Nationwide Fund Advisors purchased a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $2,074,000. Wellington Management Group LLP increased its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $1,870,000. Finally, Royal Bank of Canada increased its position in shares of Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after buying an additional 8,650 shares during the last quarter. Hedge funds and other institutional investors own 68.56% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.